scholarly journals Manual Development and Pilot Randomised Controlled Trial of Mindfulness-Based Cognitive Therapy Versus Usual Care for Parents with a History of Depression

Mindfulness ◽  
2016 ◽  
Vol 7 (5) ◽  
pp. 1024-1033 ◽  
Author(s):  
Joanna Mann ◽  
Willem Kuyken ◽  
Heather O’Mahen ◽  
Obioha C. Ukoumunne ◽  
Alison Evans ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Usual Care ◽  
Cognitive Therapy ◽  
Controlled Trial ◽  
Pilot Randomised Controlled Trial ◽  
History Of ◽  
Randomised Controlled ◽  
History Of Depression

scholarly journals Efficacy of mindfulness-based cognitive therapy in relation to prior history of depression: randomised controlled trial

2012 ◽  
Vol 201 (4) ◽  
pp. 320-325 ◽  
Author(s):  
Nicole Geschwind ◽  
Frenk Peeters ◽  
Marcus Huibers ◽  
Jim van Os ◽  
Marieke Wichers
Keyword(s):  
Depressive Symptoms ◽  
Randomised Controlled Trial ◽  
Cognitive Therapy ◽  
Rating Scale ◽  
Controlled Trial ◽  
Prior History ◽  
History Of ◽  
Randomised Controlled ◽  
Depressive Episodes ◽  
History Of Depression

BackgroundThere appears to be consensus that patients with only one or two prior depressive episodes do not benefit from treatment with mindfulness-based cognitive therapy (MBCT).AimsTo investigate whether the effect of MBCT on residual depressive symptoms is contingent on the number of previous depressive episodes (trial number NTR1084).MethodCurrently non-depressed adults with residual depressive symptoms and a history of depression ($2 prior episodes: n = 71; $3 episodes: n = 59) were randomised to MBCT (n = 64) or a waiting list (control: n = 66) in an open-label, randomised controlled trial. The main outcome measured was the reduction in residual depressive symptoms (Hamilton Rating Scale for Depression, HRSD-17).ResultsMindfulness-based cognitive therapy was superior to the control condition across subgroups (β =–0.56, P<0.001). The interaction between treatment and subgroup was not significant (β = 0.45, P = 0.16).ConclusionsMindfulness-based cognitive therapy reduces residual depressive symptoms irrespective of the number of previous episodes of major depression.

scholarly journals Pilot randomised controlled trial of protective socks against usual care to reduce skin tears in high risk people: ‘stopcuts’

Trials ◽  
2015 ◽  
Vol 16 (S2) ◽  
Author(s):  
Roy Powell ◽  
Christopher Hayward ◽  
Caroline Snelgrove ◽  
Kathleen Polverino ◽  
Linda Park ◽  
...  
Keyword(s):  
High Risk ◽  
Randomised Controlled Trial ◽  
Usual Care ◽  
Controlled Trial ◽  
Pilot Randomised Controlled Trial ◽  
Skin Tears ◽  
Randomised Controlled ◽  
Protective Socks

scholarly journals PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma

BMJ Open ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. e033176
Author(s):  
Orla McCourt ◽  
Abigail Fisher ◽  
Gita Ramdharry ◽  
Anna L Roberts ◽  
Joanne Land ◽  
...  
Keyword(s):  
Stem Cell ◽  
Randomised Controlled Trial ◽  
Stem Cell Transplantation ◽  
Usual Care ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Exercise Intervention ◽  
Controlled Trial ◽  
Pilot Randomised Controlled Trial ◽  
Randomised Controlled

IntroductionMyeloma, a blood cancer originating from plasma cells, is the most common indication for autologous stem cell transplantation (SCT). Patients with myeloma undergoing autologous SCT (ASCT) experience treatment-related morbidity and reduction in function and well-being for many months post-treatment. Interventions targeting physical functioning delivered prior to and during SCT have shown promising results in mixed haematological populations and may offer a non-pharmacological solution to physically optimising and preparing patients for SCT. The aim of this study is to investigate the feasibility of a physiotherapist-led exercise intervention as an integral part of the myeloma ASCT pathway at a UK tertiary centre.Methods and analysisPERCEPT is a single-site, pilot randomised controlled trial of an exercise intervention embedded within the myeloma ASCT pathway, compared with usual care. The primary study end points will be feasibility measures of study and intervention delivery including recruitment rates, acceptability of intervention, study completion rate and any adverse events. Secondary end points will evaluate differences between the exercise intervention group and the usual care control group in cancer-related fatigue, quality of life, functional capacity (6 min walk test; handheld dynamometry; a timed sit-to-stand test) and objective and self-reported physical activity. Outcomes will be assessed at four time points, approximately 6–8 weeks prior to SCT, on/around day of SCT, on discharge from SCT hospital admission and 12 weeks post-discharge. The exercise intervention comprises of partly supervised physiotherapist-led aerobic and resistance exercise including behaviour change techniques to promote change in exercise behaviour. The primary outcomes from the trial will be summarised as percentages or mean values with 95% CIs. Group differences for secondary outcomes at each time point will be analysed using appropriate statistical models.Ethics and disseminationThis study has NHS REC approval (Camden and Kings Cross, 19/LO/0204). Results will be disseminated through publication and presentations at haematology and rehabilitation-related meetings.Trial registration numberISRCTN15875290.

scholarly journals Acceptability and feasibility of two interventions in the MooDFOOD Trial: a food-related depression prevention randomised controlled trial in overweight adults with subsyndromal symptoms of depression

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e034025
Author(s):  
Matthew Owens ◽  
Edward Watkins ◽  
Mariska Bot ◽  
Ingeborg Annemarie Brouwer ◽  
Miquel Roca ◽  
...  
Keyword(s):  
Depressive Symptoms ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Secondary Outcome ◽  
Depression Prevention ◽  
History Of ◽  
Randomised Controlled ◽  
Subsyndromal Symptoms ◽  
Overweight Adults ◽  
History Of Depression

ObjectivesWe report on the acceptability, feasibility, dose-response relationship and adherence of two nutritional strategies to improve mood (multinutrient supplements; food-related behavioural activation (F-BA)) studied in a randomised controlled depression prevention trial (the Multi‐country cOllaborative project on the rOle of Diet, Food‐related behaviour, and Obesity in the prevention of Depression (MooDFOOD) Trial). We also assessed baseline determinants of adherence and assessed whether better adherence resulted in lower depressive symptoms.DesignRandomised controlled trial with a 2×2 factorial design conducted between 2015 and 2017.SettingGermany, the Netherlands, UK and Spain.ParticipantsCommunity sample of 1025 overweight adults with elevated depressive symptoms without a current episode of major depressive disorder. Main eligibility criteria included age (18–75 years), being overweight or obese, and having at least mild depressive symptoms, shown by a Patient Health Questionnaire Score of ≥5. A total of 76% of the sample was retained at the 12-month follow-up.InterventionsDaily nutritional supplements versus pill placebo or an F-BA therapy, delivered in individual and group sessions versus no behavioural intervention over a 1-year period.Primary and secondary outcome measuresPrimary outcome: self-reported acceptability of the interventions. Secondary outcomes: adherence and self-reported depressive symptoms.ResultsMost participants reported that the F-BA was acceptable (83.61%), feasible to do (65.91%) and would recommend it to a friend (84.57%). Individual F-BA sessions (88.10%) were significantly more often rated as positive than group F-BA sessions (70.17%) and supplements (28.59%). There were statistically significant reductions in depressive symptoms for those who both adhered to the F-BA intervention and had a history of depression (B=−0.08, SE=0.03, p=0.012) versus those who had no history of depression. Supplement intake had no effect on depressive symptoms irrespective of adherence.ConclusionsF-BA may have scope for development as a depression prevention intervention and public health strategy but further refinement and testing are needed.Trial registration numberNCT02529423.

scholarly journals Beating Adolescent Self-Harm (BASH): a randomised controlled trial comparing usual care versus usual care plus a smartphone self-harm prevention app (BlueIce) in young adolescents aged 12–17 who self-harm: study protocol

BMJ Open ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. e049859
Author(s):  
Isobel Greenhalgh ◽  
Jessica Tingley ◽  
Gordon Taylor ◽  
Antonieta Medina-Lara ◽  
Shelley Rhodes ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Young People ◽  
Health Service ◽  
Usual Care ◽  
Controlled Trial ◽  
South Central ◽  
History Of ◽  
Self Harm ◽  
Randomised Controlled ◽  
Utilisation Data

IntroductionA mobile app, BlueIce, was codesigned with young people with a history of self-harm to provide them with more accessible and available evidence-based support at times of distress. A preliminary evaluation found that BlueIce was acceptable, safe and used by young people and helped to reduce self-harm. The present study is designed to assess the effectiveness and cost-effectiveness of adding BlueIce to usual Child and Adolescent Mental Health Service (CAMHS).Methods and analysisThis study is a single-blind, randomised controlled trial comparing usual CAMHS care with usual care plus BlueIce. A total of 138 adolescents aged 12–17 with current or a history of self-harm will be recruited through the Oxford Health National Health Service (NHS) Foundation Trust via their CAMHS clinician. The primary outcome is self-harm at 12 weeks assessed using the Risk Taking and Self-Harm Inventory for Adolescents. Secondary outcomes include mood, anxiety, hopelessness, general behaviour, sleep and impact on everyday life at 12 weeks and 6 months. Health-related quality of life and healthcare resource utilisation data will be collected at baseline, 12 weeks and 6 months. Postuse interviews at 12 weeks will determine the acceptability, safety and usability of BlueIce.Ethics and disseminationThe study was approved by the NHS South Central—Oxford B NHS Research Ethics Committee (19/SC/0212) and by the Health Research Authority (HRA) and Health and Care Research Wales. Findings will be disseminated in peer review open-access journals and at academic conferences.Trial registration numberISRCTN10541045.

Sign in / Sign up

Export Citation Format

Share Document